Nalaganje...
The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series
BACKGROUND: The TNF-α antagonist golimumab is approved for the treatment of ulcerative colitis but not for Crohn's disease (CD). We herein report a case series of 8 difficult-to-treat patients with severe and refractory CD receiving golimumab as an off-label rescue medication and fourth-line an...
Shranjeno v:
| izdano v: | Inflamm Intest Dis |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
S. Karger AG
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5988172/ https://ncbi.nlm.nih.gov/pubmed/30018964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000481400 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|